XFOR Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . X4 Pharmaceuticals
XFOR Stock  USD 2.13  0.31  17.03%   
X4 Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing X4 Pharmaceuticals' valuation are provided below:
Gross Profit
25.9 M
Profit Margin
0.4654
Market Capitalization
13.1 M
Enterprise Value Revenue
0.1325
Revenue
31.4 M
There are over one hundred nineteen available fundamental measures for X4 Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to confirm X4 Pharmaceuticals' latest fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 07/28/2025, Market Cap is likely to drop to about 4.3 B. In addition to that, Enterprise Value is likely to drop to about 4.3 B

X4 Pharmaceuticals Total Revenue

1.47 Million

Check X4 Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among X4 Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 6.1 M, Depreciation And Amortization of 782.2 K or Interest Expense of 9.2 M, as well as many indicators such as Price To Sales Ratio of 819, Dividend Yield of 0.0 or PTB Ratio of 210. XFOR financial statements analysis is a perfect complement when working with X4 Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with XFOR Stock
Check out the analysis of X4 Pharmaceuticals Correlation against competitors.
To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

X4 Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets108.3 M146.4 M71.3 M
Slightly volatile
Short and Long Term Debt Total82 M78.1 M27.4 M
Slightly volatile
Other Current Liabilities25.5 M24.3 M8 M
Slightly volatile
Total Current Liabilities34.5 M32.9 M13.3 M
Slightly volatile
Property Plant And Equipment Net4.8 M4.8 M3.2 M
Slightly volatile
Current Deferred Revenue1.2 M847.5 K760.4 K
Slightly volatile
Accounts Payable4.3 M8.6 M2.9 M
Slightly volatile
Cash74.9 M55.7 M49.3 M
Slightly volatile
Non Current Assets Total21 M34.3 M13.6 M
Slightly volatile
Cash And Short Term Investments81.6 M102.1 M53.6 M
Slightly volatile
Net Receivables1.2 M1.7 M1.5 M
Slightly volatile
Common Stock Total Equity147.3 K140.3 K45.2 K
Slightly volatile
Common Stock Shares Outstanding211.1 M201.1 M55.2 M
Slightly volatile
Liabilities And Stockholders Equity108.3 M146.4 M71.3 M
Slightly volatile
Non Current Liabilities Total48 M91.4 M41.9 M
Slightly volatile
Other Current Assets3.6 M5.6 M2.3 M
Slightly volatile
Total Liabilities63.9 M124.3 M54 M
Slightly volatile
Property Plant And Equipment Gross5.2 M6.7 M3.5 M
Slightly volatile
Total Current Assets87.3 M112.2 M57.7 M
Slightly volatile
Short Term Debt1.8 M1.3 M2.1 M
Pretty Stable
Common Stock179.6 K171 K46 K
Slightly volatile
Other Liabilities28.1 M26.8 M6.9 M
Slightly volatile
Long Term Debt79.2 M75.4 M26 M
Slightly volatile
Short and Long Term Debt1.8 M1.2 M3 M
Slightly volatile
Non Current Liabilities Other766.5 K831 K472.5 K
Slightly volatile
Property Plant Equipment1.2 M1.3 M1.7 M
Slightly volatile
Long Term Debt Total13.9 M23.1 M14 M
Slightly volatile
Capital Surpluse283.1 M518.4 M252.8 M
Slightly volatile
Net Invested Capital105.2 M97.6 M85.4 M
Slightly volatile
Net Working Capital89.2 M79.3 M76.2 M
Slightly volatile
Capital Stock179.6 K171 K52.2 K
Slightly volatile
Good Will16.5 M15.6 M23.9 M
Slightly volatile
Capital Lease Obligations3.3 M2.7 M3.4 M
Slightly volatile
Deferred Long Term Liabilities18.5 M20.8 M22.7 M
Slightly volatile
Intangible Assets8 M9 M9.8 M
Slightly volatile

X4 Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income6.1 M5.8 M1.4 M
Slightly volatile
Depreciation And Amortization782.2 K796 K614.9 K
Slightly volatile
Interest Expense9.2 M8.8 M2.8 M
Slightly volatile
Selling General Administrative64.6 M61.5 M18.4 M
Slightly volatile
Other Operating Expenses58.7 M39 M41 M
Slightly volatile
Research Development46.8 M81.6 M33.5 M
Slightly volatile
Cost Of Revenue1 M797 K828.8 K
Slightly volatile
Total Operating Expenses58.6 M38.2 M40.9 M
Slightly volatile
Income Tax Expense294.5 K310 K964.5 K
Very volatile
Reconciled Depreciation425.3 K796 K305.2 K
Slightly volatile
Tax Provision325.5 K310 K148 K
Pretty Stable

X4 Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.7 M8.2 M3 M
Slightly volatile
Begin Period Cash Flow67.9 M100.2 M44.8 M
Slightly volatile
Depreciation407.6 K796 K378.6 K
Slightly volatile
Capital Expenditures325.5 K326 K258.4 K
Pretty Stable
End Period Cash Flow75.9 M56.5 M50 M
Slightly volatile
Dividends Paid10.2610.827 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8191.6 K663
Slightly volatile
Days Sales Outstanding240281260
Slightly volatile
Stock Based Compensation To Revenue1.772.892.0222
Slightly volatile
Capex To Depreciation0.70.40950.723
Pretty Stable
EV To Sales8161.6 K659
Slightly volatile
Inventory Turnover0.290.250.2795
Pretty Stable
Days Of Inventory On Hand1.3 K1.5 K1.4 K
Slightly volatile
Payables Turnover0.08780.09240.5008
Slightly volatile
Sales General And Administrative To Revenue4.96.285.8383
Slightly volatile
Research And Ddevelopement To Revenue14.628.7415.4214
Slightly volatile
Capex To Revenue0.160.110.103
Slightly volatile
Cash Per Share0.480.507618.0055
Very volatile
Days Payables Outstanding4.1 K3.9 K1.5 K
Slightly volatile
Income Quality3.673.49541.2014
Slightly volatile
Intangibles To Total Assets0.180.18680.1657
Pretty Stable
Current Ratio4.823.4124.4558
Slightly volatile
Receivables Turnover1.61.351.5623
Slightly volatile
Capex Per Share0.00150.00160.0222
Very volatile
Revenue Per Share0.01390.01464.7015
Slightly volatile
Interest Debt Per Share0.410.4324.4282
Very volatile
Debt To Assets0.560.53320.5906
Slightly volatile
Operating Cycle9071.8 K1.2 K
Pretty Stable
Days Of Payables Outstanding4.1 K3.9 K1.5 K
Slightly volatile
Ebt Per Ebit0.781.02030.9424
Slightly volatile
Quick Ratio4.83.32634.4398
Slightly volatile
Net Income Per E B T1.111.00831.0526
Slightly volatile
Cash Ratio1.611.69423.8059
Slightly volatile
Days Of Inventory Outstanding1.3 K1.5 K1.4 K
Slightly volatile
Days Of Sales Outstanding240281260
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00251.0156
Pretty Stable
Fixed Asset Turnover0.580.617.1221
Slightly volatile
Debt Ratio0.560.53320.5906
Slightly volatile
Price Sales Ratio8191.6 K663
Slightly volatile
Asset Turnover0.01910.02010.0635
Slightly volatile
Gross Profit Margin0.910.790.8673
Slightly volatile

X4 Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.3 B4.4 B6.3 B
Slightly volatile
Enterprise Value4.3 B4.4 B6.3 B
Slightly volatile

XFOR Fundamental Market Drivers

Cash And Short Term Investments102.1 M

XFOR Upcoming Events

19th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About X4 Pharmaceuticals Financial Statements

X4 Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although X4 Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in X4 Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on X4 Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue847.5 K1.2 M
Cost Of Revenue797 K1 M
Total Revenue2.6 M1.5 M
Stock Based Compensation To Revenue 2.89  1.77 
Sales General And Administrative To Revenue 6.28  4.90 
Research And Ddevelopement To Revenue 28.74  14.60 
Capex To Revenue 0.11  0.16 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(16.37)(17.19)

Pair Trading with X4 Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with XFOR Stock

  0.65ERNA Eterna TherapeuticsPairCorr

Moving against XFOR Stock

  0.79ZOTA Zota Health CarePairCorr
  0.78PTHL Pheton Holdings TrendingPairCorr
  0.77PFE Pfizer Inc Earnings Call Next WeekPairCorr
  0.72A Agilent Technologies Earnings Call TomorrowPairCorr
  0.71CICHF China Construction BankPairCorr
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for XFOR Stock Analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY